Guardant Health (GH) Stock Research

Tuesday

Guardant Health price target raised by $10 at Morgan Stanley

Aug 4, 8:01 AM

Guardant Health price target raised by $25 at Stephens, here's why

Aug 4, 7:09 AM

Guardant Health price target raised by $58 at Piper Sandler, here's why

Aug 4, 6:51 AM

Monday

Guardant Health price target raised by $50 at Stifel, here's why

Aug 3, 6:43 AM

Over a week ago

Guardant Health price target raised by $15 at RBC Capital, here's why

Jul 31, 10:10 AM

Guardant Health price target raised by $10 at TD Cowen, here's why

Jul 31, 8:49 AM

Guardant Health price target raised by $5 at BTIG, here's why

Jul 31, 8:04 AM

Guardant Health price target raised by $10 at JPMorgan

Jul 31, 7:49 AM

Guardant Health price target raised by $25 at Mizuho

Jul 31, 7:30 AM

Guardant Health price target raised by $25 at Goldman Sachs

Jul 31, 7:13 AM

Guardant Health price target raised by $50 at Barclays, here's why

Jul 31, 5:06 AM

Closing Bell Movers: Apple slides 6% after soft guidance

+18

Jul 30, 8:08 PM

Guardant Health files automatic mixed securities shelf

Jul 30, 5:32 PM

Guardant Health raises FY26 revenue view to $1.34B-$1.36B from $1.3B-$1.32B

Jul 30, 4:23 PM

Guardant Health reports Q2 adjusted EPS (42c), consensus (39c)

Jul 30, 4:22 PM

Guardant Health price target raised by $30 at Guggenheim, here's why

Jul 16, 6:57 AM

Guardant Health price target raised by $73 at TD Cowen, here's why

Jul 15, 8:49 AM

Guardant Health price target raised by $70 at Canaccord, here's why

Jul 14, 6:50 AM

Guardant Health price target raised by $45 at Morgan Stanley, here's why

Jul 9, 6:58 AM

Guardant Health price target raised by $65 at Citi

Jul 8, 6:44 AM

Guardant Health price target raised by $40 at Evercore ISI, here's why

Jul 6, 8:43 AM

Guardant Health price target raised by $55 at BofA, here's why

Jul 6, 6:34 AM

Guardant news 'meaningful positive' but impact modest, says TD

Jul 2, 9:03 AM

Guardant Health price target raised by $25 at Bernstein, here's why

Jul 2, 7:20 AM

Guardant Health Shield blood test now covered by UnitedHealth

Jul 1, 2:59 PM

Pioneering Liquid Biopsy Technology: Guardant Health was an early innovator and remains a leader in the liquid biopsy space, particularly with their well-established Guardant360 test for advanced cancer. This first-mover advantage and proven track record have built significant trust and market share.

Extensive Clinical Validation and Evidence Base: Their diagnostic tests are backed by a substantial body of peer-reviewed clinical data and real-world evidence, demonstrating high accuracy, sensitivity, and specificity. This robust validation is crucial for physician adoption and payer reimbursement.

Comprehensive Product Portfolio and Pipeline: GH offers a range of liquid biopsy solutions for various stages of cancer care, from treatment selection (Guardant360) and recurrence monitoring (GuardantReveal) to early cancer detection (Shield). This broad offering addresses multiple market segments and reduces reliance on a single product.

Intense Market Competition: The liquid biopsy and precision oncology market is highly competitive, with established diagnostic companies, large pharmaceutical firms, and numerous startups vying for market share. Competitors may develop more effective, less costly, or more widely adopted tests, potentially eroding Guardant Health's market position.

Regulatory Approval Hurdles: Guardant Health's products require rigorous regulatory approvals, primarily from the FDA in the U.S. The approval process is lengthy, expensive, and uncertain, with potential for delays or outright rejections that could significantly impact market entry and commercialization.

Reimbursement Challenges: Securing favorable reimbursement policies from government payers (e.g., Medicare) and private insurers is crucial for commercial success. Unfavorable coverage decisions, delays in payment, or reductions in reimbursement rates could severely constrain revenue growth and profitability.

Charts